Literature DB >> 24431462

Effects of neuregulin 3 genotype on human prefrontal cortex physiology.

Heike Tost1, Joseph H Callicott, Roberta Rasetti, Radhakrishna Vakkalanka, Venkata S Mattay, Daniel R Weinberger, Amanda J Law.   

Abstract

The neuregulin 3 gene (NRG3) plays pleiotropic roles in neurodevelopment and is a putative susceptibility locus for schizophrenia. Specifically, the T allele of NRG3 rs10748842 has been associated with illness risk, altered cognitive function, and the expression of a novel splice isoform in prefrontal cortex (PFC), but the neural system effects are unexplored. Here, we report an association between rs10748842 and PFC physiology as measured by functional magnetic resonance imaging of human working memory performance, where a convincing link between increased genetic risk for schizophrenia and increased activation in some PFC areas has been established. In 410 control individuals (195 males, 215 females), we detected a highly significant effect of NRG3 genotype manifesting as an unanticipated increase in ventrolateral PFC activation in nonrisk-associated C allele carriers. An additional analysis including 78 patients with schizophrenia spectrum disorders (64 males, 14 females) and 123 unaffected siblings (53 males, 70 females) revealed a whole-brain significant genotype by group interaction in right dorsolateral PFC (DLPFC), manifesting as a relative activation increase in healthy controls and siblings (C > T/T) and as a hypoactivation in patients (T/T > C). These observed genotype-dependent effects in PFC were not explained by task performance and did not conform to established locales of prefrontal inefficiency linked to genetic risk for schizophrenia. Our data indicate a complex modulation of brain physiology by rs10748842, which does not fit the simple inefficiency model of risk association in DLPFC and suggests that other neurobiological mechanisms are involved.

Entities:  

Keywords:  ErbB4; NRG3; Neuregulin; genetics; neuroimaging; schizophrenia

Mesh:

Substances:

Year:  2014        PMID: 24431462      PMCID: PMC3891948          DOI: 10.1523/JNEUROSCI.3496-13.2014

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  25 in total

1.  Stop-signal inhibition disrupted by damage to right inferior frontal gyrus in humans.

Authors:  Adam R Aron; Paul C Fletcher; Ed T Bullmore; Barbara J Sahakian; Trevor W Robbins
Journal:  Nat Neurosci       Date:  2003-02       Impact factor: 24.884

2.  Altered cortical network dynamics: a potential intermediate phenotype for schizophrenia and association with ZNF804A.

Authors:  Roberta Rasetti; Fabio Sambataro; Qiang Chen; Joseph H Callicott; Venkata S Mattay; Daniel R Weinberger
Journal:  Arch Gen Psychiatry       Date:  2011-08-01

3.  Neuregulin 3 (NRG3) as a susceptibility gene in a schizophrenia subtype with florid delusions and relatively spared cognition.

Authors:  B Morar; M Dragović; F A V Waters; D Chandler; L Kalaydjieva; A Jablensky
Journal:  Mol Psychiatry       Date:  2010-06-15       Impact factor: 15.992

4.  Altered hippocampal-parahippocampal function during stimulus encoding: a potential indicator of genetic liability for schizophrenia.

Authors:  Roberta Rasetti; Venkata S Mattay; Michael G White; Fabio Sambataro; Jamie E Podell; Brad Zoltick; Qiang Chen; Karen F Berman; Joseph H Callicott; Daniel R Weinberger
Journal:  JAMA Psychiatry       Date:  2014-03       Impact factor: 21.596

5.  Altered cerebral response during cognitive control: a potential indicator of genetic liability for schizophrenia.

Authors:  Fabio Sambataro; Venkata S Mattay; Kristina Thurin; Martin Safrin; Roberta Rasetti; Giuseppe Blasi; Joseph H Callicott; Daniel R Weinberger
Journal:  Neuropsychopharmacology       Date:  2012-12-05       Impact factor: 7.853

Review 6.  Intermediate phenotypes in psychiatric disorders.

Authors:  Roberta Rasetti; Daniel R Weinberger
Journal:  Curr Opin Genet Dev       Date:  2011-03-04       Impact factor: 5.578

7.  Common genetic variation in Neuregulin 3 (NRG3) influences risk for schizophrenia and impacts NRG3 expression in human brain.

Authors:  Wee-Tin Kao; Yanhong Wang; Joel E Kleinman; Barbara K Lipska; Thomas M Hyde; Daniel R Weinberger; Amanda J Law
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-16       Impact factor: 11.205

8.  Neuregulin 3 is associated with attention deficits in schizophrenia and bipolar disorder.

Authors:  Sandra Meier; Jana Strohmaier; Rene Breuer; Manuel Mattheisen; Franziska Degenhardt; Thomas W Mühleisen; Thomas G Schulze; Markus M Nöthen; Sven Cichon; Marcella Rietschel; Stefan Wüst
Journal:  Int J Neuropsychopharmacol       Date:  2012-07-25       Impact factor: 5.176

9.  Elucidating the genetic architecture of familial schizophrenia using rare copy number variant and linkage scans.

Authors:  Bin Xu; Abigail Woodroffe; Laura Rodriguez-Murillo; J Louw Roos; Elizabeth J van Rensburg; Gonçalo R Abecasis; Joseph A Gogos; Maria Karayiorgou
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-11       Impact factor: 11.205

10.  Schizophrenia miR-137 locus risk genotype is associated with dorsolateral prefrontal cortex hyperactivation.

Authors:  Theo G M van Erp; Ilaria Guella; Marquis P Vawter; Jessica Turner; Gregory G Brown; Gregory McCarthy; Douglas N Greve; Gary H Glover; Vince D Calhoun; Kelvin O Lim; Juan R Bustillo; Aysenil Belger; Judith M Ford; Daniel H Mathalon; Michele Diaz; Adrian Preda; Dana Nguyen; Fabio Macciardi; Steven G Potkin
Journal:  Biol Psychiatry       Date:  2013-08-01       Impact factor: 13.382

View more
  14 in total

Review 1.  Integrative Review of Genetic Factors Influencing Neurodevelopmental Outcomes in Preterm Infants.

Authors:  Lisa M Blair; Rita H Pickler; Cindy Anderson
Journal:  Biol Res Nurs       Date:  2015-09-15       Impact factor: 2.522

Review 2.  Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies.

Authors:  Colm M P O'Tuathaigh; Paula M Moran; Xuechu C Zhen; John L Waddington
Journal:  Br J Pharmacol       Date:  2017-08-03       Impact factor: 8.739

3.  NIMH neuropsychiatric genomics: crucial foundational accomplishments and the extensive challenges that remain.

Authors:  D L Braff
Journal:  Mol Psychiatry       Date:  2017-09-26       Impact factor: 15.992

4.  Temporal, Diagnostic, and Tissue-Specific Regulation of NRG3 Isoform Expression in Human Brain Development and Affective Disorders.

Authors:  Clare Paterson; Yanhong Wang; Thomas M Hyde; Daniel R Weinberger; Joel E Kleinman; Amanda J Law
Journal:  Am J Psychiatry       Date:  2016-10-24       Impact factor: 18.112

Review 5.  Neuregulin 3 and its roles in schizophrenia risk and presentation.

Authors:  Dimitrios Avramopoulos
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2017-05-29       Impact factor: 3.568

6.  Genome-wide Association of Endophenotypes for Schizophrenia From the Consortium on the Genetics of Schizophrenia (COGS) Study.

Authors:  Tiffany A Greenwood; Laura C Lazzeroni; Adam X Maihofer; Neal R Swerdlow; Monica E Calkins; Robert Freedman; Michael F Green; Gregory A Light; Caroline M Nievergelt; Keith H Nuechterlein; Allen D Radant; Larry J Siever; Jeremy M Silverman; William S Stone; Catherine A Sugar; Debby W Tsuang; Ming T Tsuang; Bruce I Turetsky; Ruben C Gur; Raquel E Gur; David L Braff
Journal:  JAMA Psychiatry       Date:  2019-12-01       Impact factor: 21.596

7.  Structural Similarities between Neuregulin 1-3 Isoforms Determine Their Subcellular Distribution and Signaling Mode in Central Neurons.

Authors:  Detlef Vullhorst; Tanveer Ahmad; Irina Karavanova; Carolyn Keating; Andres Buonanno
Journal:  J Neurosci       Date:  2017-04-21       Impact factor: 6.167

Review 8.  Neuregulin-ERBB signaling in the nervous system and neuropsychiatric diseases.

Authors:  Lin Mei; Klaus-Armin Nave
Journal:  Neuron       Date:  2014-07-02       Impact factor: 17.173

9.  Neuregulin 3 Knockout Mice Exhibit Behaviors Consistent with Psychotic Disorders.

Authors:  Lindsay N Hayes; Alexey Shevelkin; Mariela Zeledon; Gary Steel; Pei-Lung Chen; Cassandra Obie; Ann Pulver; Dimitrios Avramopoulos; David Valle; Akira Sawa; Mikhail V Pletnikov
Journal:  Mol Neuropsychiatry       Date:  2016-05-20

Review 10.  Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets.

Authors:  Matej Ľupták; Danica Michaličková; Zdeněk Fišar; Eva Kitzlerová; Jana Hroudová
Journal:  World J Psychiatry       Date:  2021-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.